Search

Your search keyword '"Maria Saigi"' showing total 2 results
Start Over Author "Maria Saigi" Journal journal of clinical oncology
2 results on '"Maria Saigi"'

1. Active surveillance before sequential targeted therapy in patients with metastatic renal cell carcinoma

Author

Xavier Garcia del Muro, Núria Sala, Maria Jove, Pilar Barretina-Ginesta, Sabela Recalde, Maria Ochoa de Olza, Olatz Etxaniz, Nuria Mulet-Margalef, Albert Font, Laura Jimenez Colomo, Valentín Navarro-Perez, and Maria Saigi

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Pathology, business.industry, medicine.medical_treatment, urologic and male genital diseases, medicine.disease, Targeted therapy, Renal cell carcinoma, Internal medicine, Toxicity, medicine, In patient, business
Abstract

e15582 Background: Some patients (pts) with metastatic renal cell carcinoma (mRCC) have an indolent course. Since new target agents are not exempt from toxicity, initial active surveillance (AS) wi...

Published
2015
Full Text
View/download PDF

2. Active surveillance in asymptomatic or minimally symptomatic renal cell carcinoma: Retrospective analyses of a cohort of three oncological centers from Spain

Author

Olatz Etxaniz, Maria Pilar Barretina Ginesta, Xavier Garcia del Muro, Maria Jove, Núria Sala, Nuria Mulet, Maria Saigi, Sabela Recalde, Maria Ochoa de Olza, Albert Font, Valentín Navarro-Perez, and Laura Jimenez Colomo

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Proportional hazards model, medicine.disease, Asymptomatic, Surgery, Oncology, Quality of life, Renal cell carcinoma, Median time, Internal medicine, Cohort, Overall survival, medicine, medicine.symptom, business
Abstract

441 Background: Some patients (pt) with metastatic renal cell carcinoma (mRCC) have an indolent course. Treatment toxicities can worsen quality of life. Active surveillance (AS) in paucisymptomatic pts is an option often used but few data is available. Our aim is to analyze the impact of initial AS in a sequential therapy strategy in terms of overall survival (OS). Methods: Data frompt diagnosed with mRCC from January 2005 to December 2013 in 3 centres of Spain were retrospectively analyzed. AS subgroup was defined as pt with ≥6 months (m) between diagnosis and first-line (L) treatment (tto) start. A descriptive analysis and median OS (mOS) were performed comparing pt with or without AS (AS vs. tto 1 year from diagnosis to M1, positively. Conclusions: Our results suggest that AS before starting first L of tto is not a detrimental action in a selected population of mRCC pt with good risk characteristics allowing them to remain free of therapy’s toxicity during a long time period.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results